tbuckley/cabot-search huggingface dataset:
Systematic Review of Randomized Controlled Trials of Exercise Interventions Using Digital Activity Trackers in Patients With Cancer
Authors: Kerry Schaffer, Narmadha Panneerselvam, Kah Poh Loh, Rachel Herrmann, Ian R. Kleckner, Richard Francis Dunne, Po-Ju Lin, Charles E. Heckler, Nicholas Gerbino, Lauren B. Bruckner, Eugene Storozynsky, Bonnie Ky, Andrea Baran, Supriya Gupta Mohile, Karen Michelle Mustian, Chunkit Fung
Journal: Journal of the National Comprehensive Cancer Network (2019)

Background: Exercise can ameliorate cancer- and treatment-related toxicities, but poor adherence to exercise regimens is a barrier. Exercise interventions using digital activity trackers (E-DATs) may improve exercise adherence, but data are limited for patients with cancer. We conducted a systematic review examining the feasibility of E-DATs in cancer survivors and effects on activity level, body composition, objective fitness outcomes, health-related quality of life (HRQoL), self-reported symptoms, and biomarkers. Methods: We identified randomized controlled trials (RCTs) of E-DATs in adult cancer survivors published in English between January 1, 2008, and July 27, 2017. Two authors independently reviewed article titles (n=160), removed duplicates (n=50), and reviewed the remaining 110 articles for eligibility. Results: A total of 12 RCTs met eligibility criteria, including 1,450 patients (mean age, 50–70 years) with the following cancers: breast (n=5), colon or breast (n=2), prostate (n=1), acute leukemia (n=1), or others (n=3). Duration of E-DATs ranged from 4 to 24 weeks, and the follow-up period ranged from 4 to 52 weeks, with retention rates of 54% to 95%. The technology component of E-DATs included pedometers (n=8); pedometers with smartphone application (n=1), Wii Fit (n=1), heart rate monitor (n=1); and a wireless sensor with accelerometer, gyroscope, and magnetometer (n=1). Adherence by at least one measure to E-DATs was >70% in 8 of 8 RCTs. Compared with controls, E-DATs significantly improved patients' step count in 3 of 5 RCTs, activity level in 6 of 9 RCTs, and HRQoL in 7 of 9 RCTs (all P≤.05), with no significant changes in biomarkers (eg, interleukin 6, tumor necrosis factor α, C-reactive protein, c-peptide, lipid panel) in 3 RCTs. Duration of E-DAT was not significantly correlated with adherence or study retention. Conclusions: This systematic review shows that E-DATs are feasible to implement in cancer survivors. Future research should examine the optimal type, dose, and schedule of E-DATs for cancer survivors.
Alcohol Intake Interacts with Functional Genetic Polymorphisms of Aldehyde Dehydrogenase (ALDH2) and Alcohol Dehydrogenase (ADH) to Increase Esophageal Squamous Cell Cancer Risk
Authors: Chen Suo, Yajun Yang, Ziyu Yuan, Tiejun Zhang, Xiaorong Yang, Tao Qing, Pei Gao, Leming Shi, Min Fan, Hongwei Cheng, Ming Lu, Li Jin, Xingdong Chen, Weimin Ye
Journal: Journal of Thoracic Oncology (2019)

Studies have reported alcohol consumption and genetic variants as major contributing factors for esophageal squamous cell carcinoma (ESCC). However, the complicated interactions between alcohol and genetic factors involved in alcohol metabolism have not been well elucidated with respect to augmented risk of ESCC.We performed a large population-based case-control study in a Chinese city with a high ESCC incidence by enrolling 1190 case patients and 1883 controls. We integrated candidate single-nucleotide polymorphism data, detailed alcohol consumption records, gene-alcohol interactions, and single-nucleotide polymorphism functional information to untangle the complicated relationship between alcohol, variants of genes encoding alcohol metabolism enzymes, and ESCC risk. The gene-alcohol interaction was tested by including their product term in a multivariable logistic regression model. Synergy index and ratio of ORs were calculated to assess interaction on additive and multiplicative scale, respectively.We confirmed two ESCC susceptibility loci, rs671 in aldehyde dehydrogenase 2 family member gene (ALDH2) and rs1042026 in alcohol dehydrogenase 1B (class I), beta polypeptide gene (ADH1B), that significantly altered alcohol consumption behavior and subsequently modified the association between alcohol consumption and ESCC risk. The rs671(A) allele was associated with ESCC risk in alcohol drinkers (adjusted odds ratio =1.98, 95% confidence interval [CI]: 1.51-2.60) but not in nondrinkers. Healthy individuals who carry different ALDH2 and ADH1B genotypes exhibit diversified drinking behavior, with the proportion of drinkers varying between 23.7% and 54.3%. Among individuals with a fast ethanol oxidization rate, we observed a strong interaction between heavy alcohol consumption and ethanal oxidization rate on both the additive scale (synergy index 4.80 [95% CI: 1.82-12.68]) and the multiplicative scale (ratio of ORs 2.93, 95% CI: 1.39-6.35).Our observation highlights the need for preventing excessive use of alcohol, especially in individuals harboring active alcohol dehyrogenase and inactive ALDH2 variants.
FRI0203 The link between copd and ankylosing spondylitis: a population based study
Authors: K. Sharif, A. Watad, S. Tiosano, Y. Yavne, D. Comanehster, A. Cohen, H. Amital
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Ankylosing spondylitis (AS) is one of the most common and severe subtypes of the spondyloarthropathies. Extra-articular involvement among AS patients, including lung disease, has been described widely. Chronic obstructive pulmonary disease (COPD) has been linked to several autoimmune diseases, however, very few studies have investigated the association between AS and COPD. <h3>Objectives</h3> To assess whether an association exists between AS and COPD. <h3>Methods</h3> A population-based cross-sectional study was conducted using data retrieved from the largest electronic medical records database in Israel, the Clalit Health Services (CHS). Patients were defined as having AS or COPD when there was at least one such documented diagnosis in their medical records. The proportion of COPD was compared between AS patients and controls. A logistic regression model was used to estimate the association between AS and COPD in a multivariate analysis adjusted for age, gender and smoking status <h3>Results</h3> The study included 4076 patients with AS and 20 290 age- and sex-frequency matched controls. The proportion of COPD in AS patients was higher than in controls (46% vs. 18%, respectively, p&lt;0.001). Multivariate logistic regression demonstrated a robust independent association between AS and COPD (OR 1.225, p=0.031). <h3>Conclusions</h3> Our study supports an association between AS and COPD, further extending the link between COPD and autoimmune diseases. This finding highlights the importance of smoking cessation in AS patients and raises the question of whether COPD screening may be warranted. <h3>Disclosure of Interest</h3> None declared
Single-nucleotide human disease mutation inactivates a blood-regenerative GATA2 enhancer
Authors: Alexandra A. Soukup, Ye Zheng, Charu Mehta, Jun Wu, Peng Liu, Miao Cao, Inga Hofmann, Yun Zhou, Jing Zhang, Kirby D. Johnson, Kyunghee Choi, Sunduz Keles, Emery H. Bresnick
Journal: Journal of Clinical Investigation (2019)

The development and function of stem and progenitor cells that produce blood cells are vital in physiology. GATA-binding protein 2 (GATA2) mutations cause GATA-2 deficiency syndrome involving immunodeficiency, myelodysplastic syndrome, and acute myeloid leukemia. GATA-2 physiological activities necessitate that it be strictly regulated, and cell type-specific enhancers fulfill this role. The +9.5 intronic enhancer harbors multiple conserved cis-elements, and germline mutations of these cis-elements are pathogenic in humans. Since mechanisms underlying how GATA2 enhancer disease mutations impact hematopoiesis and pathology are unclear, we generated mouse models of the enhancer mutations. While a multi-motif mutant was embryonically lethal, a single-nucleotide Ets motif mutant was viable, and steady-state hematopoiesis was normal. However, the Ets motif mutation abrogated stem/progenitor cell regeneration following stress. These results reveal a new mechanism in human genetics, in which a disease predisposition mutation inactivates enhancer regenerative activity, while sparing developmental activity. Mutational sensitization to stress that instigates hematopoietic failure constitutes a paradigm for GATA-2 deficiency syndrome and other contexts of GATA-2-dependent pathogenesis.
THU0693 Gout and the risk of parkinson’s disease in the elderly
Authors: J.A. Singh, J.D. Cleveland
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> A recent systematic review and meta-analysis, based on two cohort studies and three case-control studies, reported a pooled risk ratio of subsequent Parkinson's disease (PD) in patients with gout was 0.93 (95% CI, 0.79 to 1.09), a non-significant result. However, statistical heterogeneity was high at 87%–96%, indicating that studies differed from each other. Thus, it is not clear that gout is associated with PD and if so, what is the direction and magnitude of the risk of PD with gout. <h3>Objectives</h3> To assess the association of gout with the risk of incident Parkinson's disease. <h3>Methods</h3> We used the 5% Medicare sample from 2006–2012 to assess whether a diagnosis of gout was associated with the risk of incident Parkinson's disease in the elderly. Multivariable Cox regression model adjusted for demographics, Charlson-Romano comorbidity index, common medications, allopurinol and febuxostat use, was used to obtain hazard ratios (HR) and 95% confidence interval (CI). <h3>Results</h3> The mean cohort age was 73 years (standard deviation [SD], 6.5), mean Charlson-Romano comorbidity index score was 1.2 (SD, 1.9), 58% were female, 86% were White and 30% had Charlson-Romano comorbidity index score of ≥2 (n=15,675). The crude incidence rates of incident PD of 3.3 vs. 1.7 per 1000 person-years in those with gout vs. without gout. Gout was associated with a higher risk of PD in the main analysis, 1.18 (95% CI, 1.10, 1.27). Older age, male gender, White race, higher Charlson-Romano comorbidity index score were associated with higher risk of PD. Sensitivity analyses confirmed main findings. No gender or race differences were noted, but the risk differed by the age; ages 65 -&lt;75, 75 –&lt;85 and≥85 years were associated with hazard ratios of incident PD with gout of 1.27, 1.12 and 0.98, respectively. <h3>Conclusions</h3> Gout was associated with a higher risk of incident PD in the elderly. The risk of PD with gout was highest in the age group 65–75 years. Mechanisms of this increased risk need to be evaluated in future studies. <h3>Acknowledgements</h3> This material is the result of work supported by research funds from the Division of Rheumatology at the University of Alabama at Birmingham and the resources and use of facilities at the Birmingham VA Medical Centre, Birmingham, Alabama, USA. The funding body did not play any role in design, in the collection, analysis, and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. <h3>Disclosure of Interest</h3> J. Singh Grant/research support from: Takeda, Savient, Consultant for: Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta/Horizon and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology, J. Cleveland: None declared
Dementia Care Frameworks and Assistive Technologies for Their Implementation: A Review
Authors: Lefteris Koumakis, Charikleia Chatzaki, Eleni Kazantzaki, Evangelia Maniadi, Manolis Tsiknakis
Journal: IEEE Reviews in Biomedical Engineering (2019)

In this review, we focus on the various integrated care models that have been applied for the management of dementia patients. We explore the different types of assistive technologies (mobile, wearable, and home-based systems) for dementia care, with a special emphasis on technologies that involve or target the informal caregiver as end user. In an attempt to reveal the needs for information sharing, communication, and collaboration between people with dementia and caregivers involved in the effective and integrated management of the disease, we analyze the trends in research and development to date, we seek to understand and reflect upon the state of the art in assistive technologies for dementia, and we highlight domains that appear underexplored, in order to guide future research. We also explore the cost effectiveness of such technologies and integrated care models for the management of dementia patients and comment on current limitations and future trends and directions. Findings indicate the urgent need and the current lack of a comprehensive and cost-effective solution that will incorporate information system technologies for the provision of integrated care services to dementia patients and their informal caregivers.
AB0105 Effects of carrageenan induced synovitis on joint damage and pain in a rat model of knee osteoarthritis
Authors: S. Ashraf, P. Mapp, D.A. Walsh
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Knee osteoarthritis (OA) is associated with ongoing pain and joint damage that can be punctuated by acute flares of pain and inflammation. Acute synovitis in normal knees might resolve without long-term detriment to joint function. <h3>Objectives</h3> We hypothesised that osteoarthritis is associated with impaired resilience to acute inflammation. <h3>Methods</h3> We induced synovitis by intra-articular injection of carrageenan into rat knees with or without meniscal transection-induced OA, and measured synovitis, weightbearing asymmetry (an index of pain behaviour), and joint damage up to 35 days after OA induction (23 days after carrageenan-injection). <h3>Results</h3> Intra-articular injection of carrageenan was followed by weightbearing asymmetry for 1 week, synovitis, indicated by a transient increase in knee diameter for 2 days after injection, and a more sustained (through day 23) increase in synovial macrophages, endothelial cell proliferation and vascular density compared with naïve controls. Meniscal transection was followed by weightbearing asymmetry and histological evidence of OA through day 35. Carrageenan-injection in OA knees was followed for 2 days by increased weightbearing asymmetry compared either to OA knees, or to carrageenan-injected, SHAM-operated knees. OA structural damage and synovitis at day 35 were greater after carrageenan injection on day 12 compared to saline-injected, MNX-operated knees, and compared to carrageenan-injected, SHAM-operated knees. Carrageenan injection alone did not induce OA in SHAM-operated knees. <h3>Conclusions</h3> OA knees were more sensitive to pain behaviour, inflammation and structural damage following an episode of acute inflammatory pain flare than were non-arthritic knees. Preventing inflammatory flares may be particularly important in preventing symptoms and long term joint damage in OA. <h3>Disclosure of Interest</h3> None declared
Regulatory T cells mediate specific suppression by depleting peptide–MHC class II from dendritic cells
Authors: Billur Akkaya, Yoshihiro Oya, Munir Akkaya, Jafar Al Souz, Amanda H. Holstein, Olena Kamenyeva, Juraj Kabat, Ryutaro Matsumura, David W. Dorward, Deborah D. Glass, Ethan M. Shevach
Journal: Nature Immunology (2019)
Myeloid-Derived Suppressor Cells (HLA-DR-/lowCD16-CD33+) Expanded By Granulocyte Colony-Stimulating Factor Can Prevent Acute Graft-Versus-Host Disease in Humanized Mouse and Patients Following HSCT
Authors: Ke Wang, Meng Lv, Ying-Jun Chang, Xiang-Yu Zhao, Xiao-Su Zhao, Yuan-Yuan Zhang, Yu-Qian Sun, Zhi-Dong Wang, Pan Suo, Yang Zhou, Dan Liu, Shu-Zhen Zhai, Yan Hong, Yu Wang, Xiao-Hui Zhang, Lan-Ping Xu, Kaiyan Liu, Xiao-Jun Huang
Journal: Blood (2018)
Impact of Venous Thromboembolism during High Intensity Chemotherapy for Acute Leukemia Patients on Duration of Hospital Stay
Authors: Madeline Waldron, Caitlin Siebenaller, Marc Earl, Xuefei Jia, Hetty E. Carraway, Anjali S. Advani, Aziz Nazha, Aaron T. Gerds, Betty K. Hamilton, Ronald Sobecks, Matt Kalaycio, Barb Tripp, Brian P. Hobbs, Mikkael A. Sekeres, Sudipto Mukherjee
Journal: Blood (2018)
Abstract 20776: Glomerular Hyperfiltration and Microalbuminuria as Predictors of Cardiovascular Events in the Abp-International Study
Authors: Lucio Mos, Gian P Reboldi, Lawrence J Beilin, K Eguchi, Y Imai, K Kario, Sante D Pierdomenico, Francesca Saladini, Joseph H Schwartz, Paolo Palatini
Journal: Circulation (2017)

Objective: The association between glomerular hyperfiltration (GHF), microalbuminuria and cardiovascular events (CVE) is poorly known. Hypothesis: We tested the hypothesis that GHF is associated wi...
Identification, Isolation and Transcriptome Analyses of Mouse, Rat and Man Erythroblastic Island Central Macrophages
Authors: Wei Li, Yaomei Wang, Huizhi Zhao, Huan Zhang, Yuanlin Xu, Shihui Wang, Xinhua Guo, Yumin Huang, Xianfang Wu, Charles Rice, Gang Huang, Lixiang Chen, Xiuli An
Journal: Blood (2018)
Gene Therapy for Beta Thalassemia: Preliminary Results from the PHASE I/II Tiget-Bthal Trial of Autologous Hematopoietic Stem Cells Genetically Modified with GLOBE Lentiviral Vector
Authors: Sarah Marktel, Maria Pia Cicalese, Fabio Giglio, Samantha Scaramuzza, Valeria Calbi, Miriam Casiraghi, Francesca Ciotti, Maria Rosa Lidonnici, Claudia Rossi, Nicoletta Masera, Emanuela D'Angelo, Nadia Mirra, Raffaella Origa, Immacolata Tartaglione, Giacomo Mandelli, Raffaella Milani, Salvatore Gattillo, Milena Coppola, Gianluca Viarengo, Luca Santoleri, Andrea Calabria, Silverio Perrotta, Eugenio Montini, Giovanna Graziadei, Luigi Naldini, Maria Domenica Cappellini, Fabio Ciceri, Alessandro Aiuti, Giuliana Ferrari
Journal: Blood (2017)
SP0015 What’s new? presentation of the hpr newsletter
Authors: K. Betteridge
Journal: Annals of the Rheumatic Diseases (2018)

The presentation will aim to showcase HPR News – the newsletter for EULAR's Health Professionals in Rheumatology. HPR News is available twice a year and is published to support EULAR's commitment to enable networking and learning amongst HPRs across Europe. It also shares information about the work of the HPR Standing Committee, Study Groups as well as showcasing projects being carried out by HPR country member associations. The new design for the newsletter will be highlighted, alongside the content structure and HPRs will be encouraged to contribute to ensure the newsletter stays relevant to its audience. <h3>Disclosure of Interest</h3> None declared
Interferon Regulatory Factor 4 Is a Key Factor in Regulation of Thelper Cell Polarization in Graft-Versus-Host Disease
Authors: Jochen T Frueh, Bushra Rais, Daniele Yumi Sunaga-Franze, Katja Stein, Sascha Sauer, Andreas G Chiocchetti, Michael Lohoff, Evelyn Ullrich
Journal: Blood (2018)
AB0734 Serum il-35 levels in systemic sclerosis and relationship with clinical features
Authors: M.E. Yayla, M. Torğutalp, I.E. Okatan, E. Uslu Yurteri, O. Küçükşahin, A.B. Keleşoğlu Dinçer, E.G. Aydemir Gülöksüz, S. Sezer, E. Us, T.M. Turgay, G. Kınıklı, A. Ateş
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Interleukin (IL)−35 is a member of the IL-12 family. Studies show that IL-35 is an important anti-inflammatory cytokine and suppresses effector T cell activity. Systemic sclerosis (SSc) is a chronic disease characterised by vascular damage, autoimmunity and fibrosis. <h3>Objectives</h3> In this study, we aimed to evaluate serum IL-35 level in SSc patients and its potential relation with disease findings. <h3>Methods</h3> Fifty-five SSc patients and 25 healthy controls were included in the study. All patients were diagnosed according to 2013 ACR/EULAR systemic sclerosis classification criteria. Serum IL-35 was measured using a commercial ELISA kit (Cloud-Clone Corp, Wuhan, China). <h3>Results</h3> SSc patients and healthy controls had similar ages and genders. The mean of serum IL-35 level was significantly higher in SSc patients (8,2±1,3 pg/ml) than in healthy controls (6,9±0,7 pg/ml) (p &lt; 0.001). Serum IL-35 levels were similar in lcSSc (n=44) and dcSSc (n=11) groups (8.3±1.2 and 8±0,1.6 pg/ml, respectively). There were no significant relationships between serum IL-35 level and digital ulcer, interstitial lung disease, pulmonary hypertension, tendon fraction rub, gastrointestinal motility disorder, cardiac involvement and Anti-SCL70, anti-CENP-B positivities (table 1). There was not any correlation between IL-35 level and disease duration, modified Rodnan skin score, Valentini disease activity score, Medsger disease severity score, erythrocyte sedimentation rate and C-reactive protein (CRP) levels. Serum IL-35 levels between patients treated with or not vasodilating agents such as calcium channel blockers, endothelin receptor antagonists and prostaglandin analogues, and also immunosuppressive drugs did not differ significantly. <h3>Conclusions</h3> It has been reported that serum IL-35 level is higher SSc patients than healthy volunteers and is associated with interstitial lung disease. In our study, the level of IL-35 was higher SSc patients than healthy controls. There is no relationship between clinical parameters and IL-35 levels, this may be due to small sample size. Our results suggest that IL-35 may have a role on the pathogenesis of SSc. Further investigations are needed in large sample size of SSc patients. <h3>Disclosure of Interest</h3> None declared
Luspatercept improves hemoglobin levels and blood transfusion requirements in a study of patients with β-thalassemia
Authors: Antonio Piga, Silverio Perrotta, Maria Rita Gamberini, Ersi Voskaridou, Angela Melpignano, Aldo Filosa, Vincenzo Caruso, Antonello Pietrangelo, Filomena Longo, Immacolata Tartaglione, Caterina Borgna-Pignatti, Xiaosha Zhang, Abderrahmane Laadem, Matthew L. Sherman, Kenneth M. Attie
Journal: Blood (2019)